Enzo Biochem, Inc. (NYSE:ENZ) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a report released on Tuesday.

According to Zacks, “Enzo Biochem, Inc. develops, manufactures and markets health care products based on molecular biology and genetic engineering techniques, and also provides diagnostic services to the medical community. The business activities of the company are performed by one of the company’s three wholly-owned subsidiaries–Enzo Diagnostics, Inc., Enzo Therapeutics, Inc., and Enzo Clinical Labs, Inc. The primary focus of the company’s research is the development of products based on two technology platforms — genetic modulation and immune modulation. “

Shares of Enzo Biochem (NYSE:ENZ) traded up 0.33% during mid-day trading on Tuesday, hitting $9.21. The company had a trading volume of 410,231 shares. The company’s 50-day moving average is $8.62 and its 200 day moving average is $7.30. The company has a market capitalization of $426.35 million, a PE ratio of 13.52 and a beta of 1.40. Enzo Biochem has a one year low of $4.88 and a one year high of $9.68.

Enzo Biochem (NYSE:ENZ) last posted its quarterly earnings data on Monday, March 13th. The medical research company reported ($0.02) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.04) by $0.02. The company had revenue of $26.26 million during the quarter, compared to analyst estimates of $26.10 million. Enzo Biochem had a negative return on equity of 12.25% and a net margin of 37.91%. During the same quarter last year, the company earned ($0.07) earnings per share. On average, equities research analysts forecast that Enzo Biochem will post ($0.12) EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “Zacks Investment Research Downgrades Enzo Biochem, Inc. (ENZ) to Hold” was posted by American Banking News and is the property of of American Banking News. If you are reading this report on another site, it was stolen and republished in violation of international trademark and copyright legislation. The legal version of this report can be read at https://www.americanbankingnews.com/2017/05/16/zacks-investment-research-downgrades-enzo-biochem-inc-enz-to-hold.html.

A number of large investors have recently modified their holdings of ENZ. Russell Investments Group Ltd. purchased a new stake in shares of Enzo Biochem during the fourth quarter valued at about $1,072,000. Putnam Investments LLC purchased a new stake in shares of Enzo Biochem during the fourth quarter valued at about $2,254,000. Oxford Asset Management raised its stake in shares of Enzo Biochem by 40.6% in the fourth quarter. Oxford Asset Management now owns 279,038 shares of the medical research company’s stock valued at $1,937,000 after buying an additional 80,515 shares during the period. GSA Capital Partners LLP raised its stake in shares of Enzo Biochem by 64.6% in the fourth quarter. GSA Capital Partners LLP now owns 263,100 shares of the medical research company’s stock valued at $1,826,000 after buying an additional 103,292 shares during the period. Finally, Kempner Capital Management Inc. raised its stake in shares of Enzo Biochem by 36.4% in the first quarter. Kempner Capital Management Inc. now owns 95,476 shares of the medical research company’s stock valued at $799,000 after buying an additional 25,475 shares during the period. 52.71% of the stock is owned by hedge funds and other institutional investors.

About Enzo Biochem

Enzo Biochem, Inc is a bioscience company focusing on delivering and applying technology capabilities to produce products and services. The Company’s segments include Enzo Clinical Labs, Enzo Life Sciences and Enzo Therapeutics. Enzo Clinical Labs is a clinical reference laboratory providing a range of clinical services to physicians, medical centers, other clinical labs and pharmaceutical companies.

5 Day Chart for NYSE:ENZ

Get a free copy of the Zacks research report on Enzo Biochem (ENZ)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Enzo Biochem Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enzo Biochem Inc. and related companies with MarketBeat.com's FREE daily email newsletter.